Evaluating hybrid closed loop therapy for adults with type 1 diabetes from underserved communities

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to assess the effectiveness and safety of hybrid closed loop (HCL) pump therapy in adults with type 1 diabetes (T1D) from underserved communities, who typically experience higher A1c levels and complications. Participants will be randomized to receive one of three FDA-approved HCL systems or continuous glucose monitoring, with a focus on broader eligibility criteria and longer follow-up than previous studies. A mixed-methods approach will be utilized to capture user experiences and treatment outcomes. The study seeks to address disparities in diabetes management among minoritized populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of T1D for at least 12 months, on MDI for at least 6 months;
* A1c ≥7.0% with no upper limit at screening (The investigator will consider the participant A1c level, compliance with current diabetes management, and prior acute diabetic complications. For this reason, there is no upper limit on A1c specified for eligibility);
* Able to understand, speak and read English (Given the language limitations in currently available pump interfaces, subjects who are not able to understand written English will not be eligible);
* Willingness to use either lispro or aspart insulin and no other insulin or new non-insulin diabetes pharmacotherapy during the study;
* Total daily dose of insulin of at least 10 units/day;
* Investigator believes that the participant will be able to successfully adhere to the study protocol.

Exclusion Criteria:

* Current use of insulin pump or closed loop insulin pump system;
* Unable to provide informed consent;
* Currently taking hydroxyurea or have medical condition that may necessitate use of hydroxyurea;
* Current use of SGLT-2 inhibitors or sulfonylureas (If using GLP-1RA, pramlintide or metformin, must be on a stable dose for 3 months prior to enrollment);
* Tape allergy or skin condition precluding use of pump or CGM;
* Females who are pregnant or intending to become pregnant (since automated algorithm adaption for some of the HCL systems used in the trial cannot be configured to adjust to changing insulin demands of pregnancy);
* Current renal dialysis or plan to begin renal dialysis during study. Most recent eGFR \<30 ml/min is exclusionary (within last 2 years is acceptable);
* Active cancer treatment;
* Extreme visual or hearing impairment that would impair ability to use CGM and pump;
* Cognitive concerns;
* Significant psychiatric diagnosis or substance abuse disorder that in the investigator's opinion impairs ability of the individual to participate.

Where it's running

• Boston Medical Center
  Boston, Massachusetts, United States Recruiting
• Montefiore Einstein Medical Center
  The Bronx, New York, United States Recruiting

Study contacts

• Principal investigator: Howard Wolpert, MD — Boston Medical Center
• Study coordinator: Howard Wolpert, MD
• Email: howard.wolpert@bmc.org
• Phone: 617-285-9096

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing diabetes foot care using eHealth tools

  This study is testing a new way to use digital tools to help people with diabetes take better care of their feet and prevent foot ulcers.

  Recruiting Sahlgrenska University Hospital · Gothenburg · NCT05692778

• Measuring bottom-of-foot pressures in people with lateral forefoot amputation due to diabetes

  Aiming to see if people with lateral forefoot amputation due to diabetes have higher pressures under remaining foot areas while walking.

  Recruiting at 2 sites Nanyang Technological University · Singapore and 1 other locations · NCT07865208

• Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes

  This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.

  Recruiting Fidam Rdc · Bad Mergentheim, Baden-Wurttemberg · NCT07814508

• Tirzepatide for type 1 diabetes patients who are overweight or obese

  This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida · NCT07803744

• Isometric Strengthening vs. Tens in Diabetic Shoulder Pain

  This study tests whether isometric strengthening exercises or transcutaneous electrical nerve stimulation help reduce shoulder pain in people with diabetes.

  Recruiting Kafrelsheikh University · Kafr ash Shaykh · NCT07747454

• Oral insulin vs. subcutaneous insulin in adults with type 1 diabetes

  This study tests an oral insulin tablet (SCD0503) against subcutaneous insulin and placebo to see how it behaves in the blood and helps control blood sugar in adults with type 1 diabetes.

  Recruiting Phase 1 Sam Chun Dang Pharm. Co. Ltd. · Neuss, North Rhine-Westphalia · NCT07634770

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.